Meeting
2022 ASCO Annual Meeting
Real-world effectiveness of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic non–small cell lung cancer.
Authors
Lingzhi Hong
Department of Thoracic and Head and Neck Medical Oncology, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX
Lingzhi Hong , Waree Rinsurongkawong , Maliazurina B Saad , Pingjun Chen , Muhammad Aminu , Amy R. Spelman , Marcelo Vailati Negrao , Tina Cascone , Steven H. Lin , Percy Lee , Boris Sepesi , Jeff Lewis , Don Lynn Gibbons , Ara A. Vaporciyan , J. Jack Lee , Xiuning Le , Jia Wu , John Heymach , Jianjun Zhang , Natalie I Vokes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9055)
DOI
10.1200/JCO.2022.40.16_suppl.9055
Abstract #
9055
Poster Bd #
43
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2021 ASCO Annual Meeting
The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study.
First Author: Karen Kelly
Poster
2021 ASCO Annual Meeting
Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers.
First Author: Noura J. Choudhury
Poster
2020 ASCO Virtual Scientific Program
An FDA analysis of the association of tumor growth rate and overall and progression-free survival in metastatic non-small cell lung cancer (NSCLC) patients.
First Author: Yutao Gong
Poster
2024 ASCO Annual Meeting
PD-L1 expression in pulmonary sarcomatoid carcinoma and response to immunotherapy.
First Author: Lingzhi Hong